Skip to search formSkip to main contentSkip to account menu

GX15-070MS

National Institutes of Health

Related topics

Related topics

1 relation
obatoclax mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer
Although the prognosis of differentiated thyroid cancer (DTC) is relatively good, 30-40% of patients with distant metastases… 
2016
2016
Phase I study of obatoclax mesylate (GX15–070MS), a bcl-2 antagonist, plus topotecan in relapsed small cell lung carcinoma and other solid tumors
3504 Background: Bcl-2 is a rational target in SCLC since it is overexpressed in 60%-90% of tumors and may play a role in… 
2015
2015
Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells
The evasion of cell death is one of the hallmarks of cancer, contributing to both tumor progression and resistance to therapy… 
2014
2014
Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells.
Pancreatic cancer is an aggressive disease with a poor prognosis. Therefore, new treatment is urgently required. GX15-070 is a… 
2014
2014
Sequential single-agent obatoclax mesylate (GX15–070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma
2013
2013
GX 15-070 ( Obatoclax ) Induces Apoptosis and Inhibits Cathepsin Dand L – Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells
In estrogen receptor–positive (ERþ) breast cancer cells, BCL2 overexpression contributes to antiestrogen resistance. Direct… 
2011
2011
Effect of BH3-mimetics GX15-070 and ABT-737 on cisplatin resistance in malignant pleural mesothelioma cells
2009
2009
Phase I study of obatoclax mesylate (GX15-070MS), a bcl-2 antagonist, plus topotecan in relapsed small cell lung carcinoma and other solid tumors.
3504 Background: Bcl-2 is a rational target in SCLC since it is overexpressed in 60%-90% of tumors and may play a role in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)